Aerovate Therapeutics (AVTE) Competitors $7.83 -0.11 (-1.39%) As of 08/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. NUVB, CRON, OCS, QURE, SION, NAGE, MNMD, TNGX, STOK, and AMLXShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Nuvation Bio (NUVB), Cronos Group (CRON), Oculis (OCS), uniQure (QURE), Sionna Therapeutics (SION), Niagen Bioscience (NAGE), Mind Medicine (MindMed) (MNMD), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Nuvation Bio Cronos Group Oculis uniQure Sionna Therapeutics Niagen Bioscience Mind Medicine (MindMed) Tango Therapeutics Stoke Therapeutics Amylyx Pharmaceuticals Nuvation Bio (NYSE:NUVB) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Do analysts prefer NUVB or AVTE? Nuvation Bio currently has a consensus price target of $7.17, indicating a potential upside of 206.92%. Given Nuvation Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Nuvation Bio is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, NUVB or AVTE? Nuvation Bio has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Does the media favor NUVB or AVTE? In the previous week, Nuvation Bio had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 7 mentions for Nuvation Bio and 1 mentions for Aerovate Therapeutics. Nuvation Bio's average media sentiment score of 0.29 beat Aerovate Therapeutics' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aerovate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in NUVB or AVTE? 61.7% of Nuvation Bio shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is NUVB or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -5,534.21%. Nuvation Bio's return on equity of -44.14% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% Aerovate Therapeutics N/A -90.19%-77.47% Which has better earnings & valuation, NUVB or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M100.95-$567.94M-$2.35-0.99Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.61 SummaryNuvation Bio beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$226.95M$785.27M$5.48B$9.56BDividend YieldN/A4.84%3.99%4.17%P/E Ratio-2.621.2929.9325.14Price / SalesN/A25.43375.2276.13Price / CashN/A19.5635.9458.58Price / Book1.986.578.105.59Net Income-$75.52M-$3.92M$3.26B$265.48M7 Day Performance8.90%-2.83%0.68%1.22%1 Month Performance-25.07%-0.30%2.45%0.39%1 Year Performance-86.84%23.98%27.72%23.47% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$7.83-1.4%N/A-86.6%$226.95MN/A-2.6220Upcoming EarningsHigh Trading VolumeNUVBNuvation Bio2.0264 of 5 stars$2.35+1.5%$7.17+205.6%-18.5%$797.91M$7.87M-1.0060News CoverageCRONCronos Group2.2565 of 5 stars$2.06+1.7%N/A+2.3%$788.73M$117.61M15.81450Earnings ReportGap UpOCSOculis3.0289 of 5 stars$17.84-0.6%$35.33+98.1%+57.6%$778.71MN/A-6.762Positive NewsQUREuniQure2.6112 of 5 stars$14.15+2.7%$36.55+158.3%+88.9%$776.14M$27.12M-3.61500SIONSionna TherapeuticsN/A$17.37+1.5%$38.50+121.6%N/A$766.36MN/A0.0035Positive NewsLockup ExpirationNAGENiagen Bioscience1.4735 of 5 stars$9.40-2.5%$13.22+40.6%N/A$740.44M$99.60M55.29120Earnings ReportGap UpMNMDMind Medicine (MindMed)2.0698 of 5 stars$9.71+3.7%$24.71+154.7%+36.7%$730.95MN/A-6.3240Trending NewsAnalyst RevisionTNGXTango Therapeutics1.9518 of 5 stars$6.73+2.1%$10.50+56.0%-24.2%$729.71M$40.99M-5.5290News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSTOKStoke Therapeutics3.9679 of 5 stars$13.01-1.0%$25.80+98.4%-3.4%$711.60M$36.56M16.50100AMLXAmylyx Pharmaceuticals2.7871 of 5 stars$7.93-0.4%$11.75+48.3%+317.0%$706.98M-$1.27M-2.55200News CoverageGap Down Related Companies and Tools Related Companies Nuvation Bio Competitors Cronos Group Competitors Oculis Competitors uniQure Competitors Sionna Therapeutics Competitors Niagen Bioscience Competitors Mind Medicine (MindMed) Competitors Tango Therapeutics Competitors Stoke Therapeutics Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
